Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Novartis buys radiopharma firm Mariana Oncology for $1 billion

by Laura Howes
May 16, 2024 | A version of this story appeared in Volume 102, Issue 15

 

Novartis is the latest drug company to buy up a radiopharmaceutical-focused biotech firm with its planned purchase of Mariana Oncology for $1 billion. Radiopharmaceuticals are not a new area for Novartis, which already sells the lutetium-177-based drugs Lutathera and Pluvicto. Mariana brings with it a roster of ligands with radionuclides that emit α and β particles. The company’s lead compound, MC-339, is an actinium-225-containing radioligand therapy to treat small-cell lung cancer.

CORRECTION:

This article was updated on June 14, 2024, to correct the isotope that Mariana Oncology’s lead compound contains. It is actinium-225, not actinium-255.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.